RTW Biotech Opportunities Ltd Baroness Blackwood Appointed as Independent NED

RNS Number : 9505V

RTW Biotech Opportunities Ltd

11 July 2024

 

LEI: 549300Q7EXQQH6KF7Z84

11 July 2024

RTW Biotech Opportunities Ltd

Baroness Nicola Blackwood Appointed as Independent Non-Executive Director

 

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, announces that Baroness Nicola Blackwood has been appointed to the Company's Board of Directors as an independent, Non-Executive Director, effective the 11th of July 2024.

 

Nicola is a leader in science and entrepreneurship. She is a member of the House of Lords, and Chair of Genomics England and Oxford University Innovation. Since 2023, she has been a Supervisory Board member of the biotechnology company, BioNTech. Nicola served as Minister for Innovation in the Department for Health and Social Care under two Prime Ministers where she led on Lifesciences, NHS Data and Digital Transformation, and Global Health Security. She was the first female MP for Oxford and was elected by MPs of all parties to Chair the Commons Science and Tech Committee. She remains one of the youngest committee chairs in British history and the only woman to have chaired the Commons Science & Tech Committee.

 

Bill Scott, Chair of the Nomination and Remuneration Committee, who led the appointment process said, "We are delighted to welcome Baroness Blackwood to the board of RTW Biotech Opportunities Ltd.  Nicola brings with her a remarkable blend of skills and experience, having operated at the highest levels of government and leadership roles in the facilitation of fundamental research and strategic commercialisation of promising innovation in life sciences both in the UK and overseas.  We look forward to working with her to take RTW Biotech Opportunities to the next level as the leading investment fund in its sector on the London market and in further advancing the UK and European biotech ecosystem."

William Simpson, Chair of the Board, said, "Nicola's involvement in science and technology, within and outside of government, provides us with significant additional knowledge from which we all will benefit.  The performance of the Company since inception has been excellent and Nicola's contribution will help us further develop our mission to harness innovation in biotech to the advantage of patients and shareholders."

Nicola Blackwood said, "I am delighted to be joining the RTW Biotech Opportunities Ltd Board. Life sciences and innovation will be central in tackling many of the global challenges we face today. I look forward to engaging with the RTW team and playing a part in powering innovations from breakthrough to high-growth companies."

 

No further details are required to be disclosed under LR 9.6.13

 

For Further Information

RTW Investments, LP	[phone]
Woody Stileman, Managing Director, Business Development Krisha McCune, Director, Investor Relations	[e-mail]
Buchanan (PR & Communications Adviser)	[phone]
Charles Ryland
Henry Wilson
George Beale
Deutsche Numis (Joint Corporate Broker)	[phone]
Freddie Barnfield
Nathan Brown
Euan Brown
BofA Securities (Joint Corporate Broker)	[phone]
Edward Peel
Alex Penney
Cadarn Capital (Distribution & IR Partner)	[phone]
David Harris
Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director	[phone]
Morgan Stanley Fund Services USA LLC	[phone]

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

 

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

BOAFBLLFZDLBBBX